[EN] ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN<br/>[FR] DÉRIVÉS D'ARYLCARBOXAMIDE EN TANT QU'INHIBITEURS DE CANAL SODIQUE POUR LE TRAITEMENT DE LA DOULEUR
申请人:AMGEN INC
公开号:WO2011103196A1
公开(公告)日:2011-08-25
The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals
wherein R
1
, R
2
, R
3
, R
4
and W are as defined herein.
Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
申请人:Peters Dan
公开号:US20070021404A1
公开(公告)日:2007-01-25
This invention relates to novel aza-ring derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS
申请人:Bregman Howard
公开号:US20130131035A1
公开(公告)日:2013-05-23
The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
申请人:Integrative Research Laboratories Sweden AB
公开号:US10875829B1
公开(公告)日:2020-12-29
The disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I): (I) or an isotope labelled analog thereof, or a pharmaceutically acceptable salt thereof, wherein: each of R1, R2, R3, R6 and R7 represents H or F, R4 represents H or CH3 R5 represents H or C1-C4alkyl, wherein at least two of R1, R2, R3, R6 and R7 represent F, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.
本公开提供了一种药物组合物,其包含治疗有效量的式(I)化合物:(I) 或其同位素标记类似物,或其药学上可接受的盐,其中:R1、R2、R3、R6 和 R7 各代表 H 或 F,R4 代表 H 或 CH3,R5 代表 H 或 C1-C4 烷基,其中 R1、R2、R3、R6 和 R7 中至少有两个代表 F,与至少一种药学上可接受的载体、赋形剂和/或稀释剂一起。